Ablation of Pulmonary Oligometastasis Combined With Systemic Therapy Compared to Systemic Therapy Alone for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study

What this Trial Is About

Researchers are investigating the use of ablation combined with systemic therapy for treating advanced hepatocellular carcinoma (HCC) with pulmonary oligometastases. Pulmonary oligometastases represent a stage between localized and widespread disease. While ablation has been effective for intrathoracic metastases from various cancers, its role specifically in HCC with lung oligometastases is still being evaluated. This multicenter retrospective study aims to provide clinical evidence on this treatment approach compared to systemic therapy alone. Participants receive either ablation of pulmonary metastases using image-guided techniques such as microwave ablation, radiofrequency ablation, or cryoablation under CT guidance combined with systemic therapy, or systemic therapy alone following treatment instructions. Ablation targets complete destruction of lung metastases. All participants have already received first-line systemic therapy and may have undergone locoregional treatments like transarterial chemoembolization or hepatic arterial infusion chemotherapy. During the study, researchers will monitor participants for progression-free survival over 12 months as the primary outcome. Secondary outcomes include overall survival at 24 months and objective response rate at 12 months. Participants will be followed with clinical assessments to evaluate tumor control and treatment effects. The study includes adults aged 18 to 80 years with controlled intrahepatic tumors and limited metastatic sites, aiming to understand the benefits and risks of adding ablation to standard systemic therapy in this population.

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma